D
65.12
-2.96 (-4.35%)
| Previous Close | 68.08 |
| Open | 68.15 |
| Volume | 3,502,918 |
| Avg. Volume (3M) | 4,750,235 |
| Market Cap | 25,537,150,976 |
| Price / Earnings (TTM) | 45.86 |
| Price / Earnings (Forward) | 25.64 |
| Price / Sales | 6.31 |
| Price / Book | 10.13 |
| 52 Weeks Range | |
| Earnings Date | 30 Oct 2025 |
| Profit Margin | 12.90% |
| Operating Margin (TTM) | 12.91% |
| Diluted EPS (TTM) | 1.33 |
| Quarterly Revenue Growth (YOY) | 12.50% |
| Quarterly Earnings Growth (YOY) | -28.00% |
| Total Debt/Equity (MRQ) | 113.97% |
| Current Ratio (MRQ) | 1.50 |
| Operating Cash Flow (TTM) | 964.10 M |
| Levered Free Cash Flow (TTM) | 509.04 M |
| Return on Assets (TTM) | 5.97% |
| Return on Equity (TTM) | 23.72% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | DexCom, Inc. | Bearish | Bearish |
AIStockmoo Score
1.0
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.0 |
| Average | 1.00 |
|
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Mid Growth |
| % Held by Insiders | 0.42% |
| % Held by Institutions | 97.10% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 106.00 (Canaccord Genuity, 62.78%) | Buy |
| 106.00 (UBS, 62.78%) | Buy | |
| Median | 99.00 (52.03%) | |
| Low | 85.00 (Stifel, 30.53%) | Buy |
| 85.00 (Citigroup, 30.53%) | Buy | |
| Average | 96.42 (48.07%) | |
| Total | 11 Buy, 1 Hold | |
| Avg. Price @ Call | 74.47 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Stifel | 21 Oct 2025 | 85.00 (30.53%) | Buy | 69.75 |
| Truist Securities | 15 Oct 2025 | 94.00 (44.35%) | Buy | 65.41 |
| Citigroup | 07 Oct 2025 | 85.00 (30.53%) | Buy | 66.03 |
| Goldman Sachs | 01 Oct 2025 | 89.00 (36.67%) | Buy | 66.08 |
| Canaccord Genuity | 29 Sep 2025 | 106.00 (62.78%) | Buy | 66.46 |
| 01 Aug 2025 | 106.00 (62.78%) | Buy | 79.28 | |
| Baird | 26 Sep 2025 | 90.00 (38.21%) | Buy | 67.10 |
| Argus Research | 21 Aug 2025 | 100.00 (53.56%) | Buy | 80.62 |
| Oppenheimer | 31 Jul 2025 | 102.00 (56.63%) | Buy | 80.77 |
| Piper Sandler | 31 Jul 2025 | 100.00 (53.56%) | Buy | 80.77 |
| Raymond James | 31 Jul 2025 | 102.00 (56.63%) | Buy | 80.77 |
| UBS | 31 Jul 2025 | 106.00 (62.78%) | Buy | 80.77 |
| Barclays | 30 Jul 2025 | 98.00 (50.49%) | Hold | 89.06 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |